Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) Logo

The stock of ENZON PHARMACEUTICALS INC (OTCMKTS:ENZN) registered an increase of 83.25% in short interest. ENZN’s total short interest was 36,100 shares in August as published by FINRA. Its up 83.25% from 19,700 shares, reported previously. With 46,800 shares average volume, it will take short sellers 1 days to cover their ENZN’s short positions.

The stock increased 5.14% or $0.0125 during the last trading session, reaching $0.2549. About 571 shares traded. Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) has 0.00% since August 10, 2018 and is . It has by 0.00% the S&P500.

Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in licensing drug products. The company has market cap of $11.27 million. The companyÂ’s marketed drug products include PegIntron for chronic hepatitis C; Sylatron for melanoma; Macugen for neovascular wet age-related macular degeneration; and CIMZIA for the treatment of rheumatoid arthritis and CrohnÂ’s disease. It has a 1.95 P/E ratio.

More notable recent Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) news were published by: Seekingalpha.com which released: “Warning! Enzon Pharmaceuticals Is Definitely Going To $0 – Seeking Alpha” on January 14, 2014, also Seekingalpha.com with their article: “Enzon Pharmaceuticals Selling Well Below Likely Future Distributions – Seeking Alpha” published on May 25, 2016, Seekingalpha.com published: “Enzon Pharmaceuticals: Remaining Royalties Priced In, But Door Still Open To Become A NOL Cash Shell – Seeking Alpha” on April 17, 2017. More interesting news about Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) were released by: Seekingalpha.com and their article: “Enzon Pharmaceuticals – Royalties Or Cash? – Seeking Alpha” published on June 19, 2019 as well as Valuewalk.com‘s news article titled: “Baupost Buys Elan Corp, DIRECTV, Sells Genworth, News Corp – ValueWalk” with publication date: May 15, 2013.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *